Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. - Wikidata - awgldk - TriplyDB

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

http://www.wikidata.org/entity/Q33814323

about

Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts.Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer Review: cancer-induced autoimmunity in the rheumatic diseases.Cancer risk in dermatomyositis: a meta-analysis of cohort studies.Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.Myositis autoantibodies and clinical phenotypes.Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.Analysis of the SUMO2 Proteome during HSV-1 Infection.Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.Polymyositis and dermatomyositis as a risk of developing cancer.Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome.The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013 Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Regional ischemic immune myopathy: a paraneoplastic dermatomyopathy.Idiopathic inflammatory myopathies-a review.A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.The Clinical Features of Myositis-Associated Autoantibodies: a Review.Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort.Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.Malignancy screening in autoimmune myositis amongst Australian Rheumatologists.Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin.Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients.Integrated classification of inflammatory myopathies.Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature.Pharmacological management of dermatomyositis.Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis.High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation.

P2860

Q30252086-90105FD6-3F35-4C1A-A503-F062CCA953B8 Q33592767-6A8EDA8C-11AB-4CCB-A628-DC11ACD5CB07 Q33670102-7876A8AD-B46F-4D38-825F-3E69CF3FA412 Q33812271-04F351C9-E003-4BF4-8133-EF7F5AC4CB96 Q34666066-7C989334-BEBE-4638-81AB-63A315F55A94 Q34668158-F676FD4A-67B0-4B25-8F2B-DE744BA1A1CD Q34791339-FB11D1B2-8603-4A40-B3E8-20B56AADA87A Q35153832-AAF3742B-70C9-47B6-9278-0EFA13381CCD Q35153899-CA77060E-E648-4CF6-9C4D-1D9E5251DA1F Q35281962-8A72F778-DDDB-4A5D-8EB4-ADF3287E4CC6 Q35454043-A303B04C-368C-47A6-856C-3FE54663E255 Q35498937-4F7575E6-1E1C-4F12-BAE6-2175991A6C80 Q35705640-6E4BDB67-F6D8-4A11-BAB8-88A1251DAEC2 Q36113525-8D25A029-7329-4821-9212-14FD0F6ABADD Q36364785-D5E1152D-EE74-4FF4-8440-338FB4833A14 Q36788809-5EB08655-76DB-4BD1-B110-E10FB0F86E2C Q36842357-777E3CE8-2500-458E-AD36-693762EA244F Q36842737-67C9A76F-9317-4574-8788-57E16DC9A74A Q37022721-C7BC1483-0921-400D-9701-A03E17CB9A02 Q37038527-B6EDC4D2-73A6-4984-BF68-23878516AB40 Q37100264-58E3CCE2-957C-4063-8B3E-CDC284A171FA Q37358050-83D0ADEF-80C7-4E0D-9F68-CF523B3AB37E Q37368405-49008C68-255F-4DDA-974D-9C01D0E4D5C1 Q38266506-53D2BD8A-E567-4A15-B805-9024F9DE5AA8 Q38355216-D7C757A5-B37B-4BDD-BF47-10401386BFE7 Q38596370-D4BD25E5-0D95-4572-B2B4-6E423246C1EE Q38603422-995AAEB6-6A18-4A79-AD38-E9A750731DDD Q38613540-36EA4782-E99C-4F69-883F-2F8EB16272F3 Q38646384-57AFA645-2321-4969-98D8-C9A5B5EB0795 Q38662460-738ED23A-7099-4F01-8A31-518BE3B93A25 Q38879035-AD148266-ADC7-40A6-9590-C70D0B3268EB Q38952138-C98B7FCB-D5C4-4ADD-951A-C3467AA72B7B Q38995102-03BC50C7-F102-421F-A551-3FA3D5EEE91B Q39027323-C89A6EDE-0DD9-41C7-8362-435CD7B177EB Q39044741-A6B9C697-FE6C-4CEB-AA2D-21599DF8C40B Q39425296-81D0F84D-2B6F-407F-9B87-091DE7893402 Q39824090-F13A9F1F-D93B-4FC6-8677-EB087EE809DE Q40725508-157DF4E1-AD97-415F-B330-58F93D0EA07C Q40795767-4D486F05-5E7F-45F4-95F2-EF27360F7C4D Q41038527-9B10F5A5-5AA6-43BF-9D0F-98A560B11875

P2860

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

http://www.wikidata.org/entity/Q33814323

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@ast

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@en

type

label

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@ast

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@en

prefLabel

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@ast

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@en

P1433

Q33814323-66C3D23D-E5E7-4014-B1BB-DEB7930C2595

P1476

Q33814323-45896EFF-DDAD-47FB-9706-A9BCE1E50F88

P2093

Q33814323-3CE7FEA6-5584-4674-B49B-AF615A118DA6

Q33814323-75770708-5B6F-4585-A584-A780A368A73D

Q33814323-83F4BC86-0199-4537-B33F-6C5EE4430F94

Q33814323-91BB1084-8C03-4918-9F76-D735ACEC7610

Q33814323-9CC12472-EDC5-40A6-9227-A6A1200AFE73

Q33814323-C33E3ABA-4C1E-41E9-97F4-C7A83547D076

Q33814323-C6BE68C1-AF2A-4EC9-85C9-784438C5225C

Q33814323-FE10E1BB-9FA4-4E9F-887F-7F81FF1C52CD

P2860

Q33814323-14C765A0-15D6-4F54-A10C-97A4ED4E1176

Q33814323-194BBD02-0B00-4261-AFC5-619F22423520

Q33814323-25490482-A7E6-4891-9C21-F7F983189F3C

Q33814323-2D95D2A9-16CD-408F-9D3A-848560CD5E0A

Q33814323-3D195FDC-8BC7-4F71-BF12-2671DB1D2BF6

Q33814323-4CED19EF-9892-4BF4-8B50-ECE8615D3566

Q33814323-51D0CBD1-6506-4943-AFB4-0F32C326F5A4

Q33814323-52429326-542A-40B8-B073-7BB357DC1D8E

Q33814323-6A252639-51D4-4065-B2E2-D8B939C9EAF2

Q33814323-6C8DA9CC-FA38-4662-BE9B-34C80A7A5009

P304

Q33814323-D5022252-0C20-4A75-9CB7-202BB7FC3755

P31

Q33814323-B4590F6C-6360-4261-A59D-074060C407D4

P356

Q33814323-9B5301A9-0516-414C-B32B-FC15877B9E3A

P433

Q33814323-D0DFF3CC-3F05-4EB5-B72D-51F9C161F621

P478

Q33814323-0EA28B6B-C74A-4A7F-91C9-EE93F0F7D704

P577

Q33814323-A47783D0-BD0B-45AE-B52E-60CC395AC804

P698

Q33814323-2B22CE7C-604C-4276-A2C4-55FDB1738385

P921

Q33814323-9F9B875F-E657-43BF-9D69-50415E60FEE4

Q33814323-A85EA35F-A50D-4280-8A2D-57F9B68AA4A4

P932

Q33814323-85E3CC8E-299F-4AFE-91E8-302571C3B199

P356

P1433

Arthritis & Rheumatology

P1476

Most patients with cancer-asso ...... iption intermediary factor 1γ.

@en

P2093

Andrew L Mammen

http://www.w3.org/2001/XMLSchema#string

Antony Rosen

http://www.w3.org/2001/XMLSchema#string

David F Fiorentino

http://www.w3.org/2001/XMLSchema#string

Lisa Christopher-Stine

http://www.w3.org/2001/XMLSchema#string

Lisa Zaba

http://www.w3.org/2001/XMLSchema#string

Livia Casciola-Rosen

http://www.w3.org/2001/XMLSchema#string

Lorinda S Chung

http://www.w3.org/2001/XMLSchema#string

Shufeng Li

http://www.w3.org/2001/XMLSchema#string

P2860

Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.

Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.

Polymyositis and dermatomyositis (first of two parts).

Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.

Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects.

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis

Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.

P304

2954-2962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.38093

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24037894

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis

P932

4073292

http://www.w3.org/2001/XMLSchema#string